Clinical trials: HCC - Hepatocellular Carcinoma, open to volunteers
Hepatocellular Carcinoma (HCC)
Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma
The goal of this clinical trial is to evaluate the combination of zanzalintinib (XL092) and tegavivint in advanced hepatocellular carcinoma (HCC) and Wnt pathway mutations who have progressed after at least one prior line of…
- Trial name
- NCT07878689
- Testing
- Zanzalintinib, Tegavivint
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Texas Southwestern Medical Center
OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC)
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
This multicenter, prospective, randomized, controlled, open-label, two-arm Phase III clinical trial is designed to evaluate whether adding radiotherapy to oligoprogressive lesions while continuing first-line systemic therapy at…
- Conditions
- OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy, Systemic Therapy
- Trial name
- NCT06841172
- Testing
- radiotherapy, Systemic therapy (Continuation of current first-line systemic therapy), Systemic therapy (Early switch to second-line systemic therapy)
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shandong Cancer Hospital and Institute
Hepatocellular Carcinoma (HCC), Liver Cancer, Adult
Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
This is a single-arm, open-label, single-center, first-in-human feasibility study evaluating parenchymal blood volume (PBV) imaging as a tool to dynamically assess perfusional changes in hepatocellular carcinoma (HCC) potentiated…
- Trial name
- NCT07682454
- Testing
- Parenchymal Blood Volume (PBV) Imaging, Nitroglycerin, Medical Record Review
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Advanced Hepatocellular Carcinoma (HCC)
Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC
This is a prospective, single-center, single-arm Phase II pilot study designed to evaluate the efficacy and safety of FMT in combination with QL1706 and Bevacizumab as first-line treatment for advanced Hepatocellular carcinoma.
- Trial name
- NCT07847671
- Testing
- FMT combined with QL1706 plus Bevacizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
Hepatocellular Carcinoma (HCC)
STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular Carcinoma
STRATHEP develops and validates a multimodal AI model to predict treatment response in advanced hepatocellular carcinoma. By integrating digital pathology and MRI radiomics, the project identifies patients likely to benefit from…
- Trial name
- STRATHEP (NCT07863258)
- Where
- 5 sites in Belgium
- Volunteers
- 280 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic
Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
ACE723 is a dual-payload antibody drug conjugate targeting glypican-3 (GPC-3) that is under investigation for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic, Hepatocellular Carcinoma Non-Resectable
- Trial name
- NCT07861425
- Testing
- ACE723
- Where
- 2 sites in China
- Volunteers
- 70 people
- Sponsor
- Acepodia Biotech, Inc.
HCC - Hepatocellular Carcinoma, Watch & Wait
Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
The "Surgery versus Maintenance after Conversion-therapy-achieved Complete/Partial Response in Hepatocellular Carcinoma (SWITCH)" study is a multicenter, open-label, prospective non-randomized cohort study with the protocol…
- Conditions
- HCC - Hepatocellular Carcinoma, Watch & Wait, Surgery
- Trial name
- SWITCH (NCT07410715)
- Testing
- Surgical Resection, Maintenance Therapy Group
- Where
- China
- Volunteers
- 100 people
- Sponsor
- West China Hospital
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
Hepatocellular Carcinoma(HCC)
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
This project is a prospective, multi-center, multi-cohort exploratory clinical study. It focuses on patients with advanced hepatocellular carcinoma who experience disease progression after first-line standard therapy.
- Trial name
- ICT-HCC (NCT06893887)
- Testing
- FOLFOX4, Adebrelimab, Apatinib
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Nanjing Tianyinshan Hospital
HCC - Hepatocellular Carcinoma, Durvalumab
Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Tremelimumab plus durvalumab (STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), yet it shows limited efficacy with an ORR of only 20.1%.
- Conditions
- HCC - Hepatocellular Carcinoma, Durvalumab, Tremelimumab, Proton Radiotherapy
- Trial name
- Proton-STRIDE (NCT06999694)
- Testing
- Proton radiotherapy, Tremelimumab, Durvalumab
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
HCC - Hepatocellular Carcinoma, Tremelimumab
Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Tremelimumab plus durvalumab (the STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC); however, it demonstrates limited efficacy, with an objective response rate (ORR) of only 20.1%.
- Conditions
- HCC - Hepatocellular Carcinoma, Tremelimumab, Durvalumab, Radiotherapy
- Trial name
- Photon-STRIDE (NCT06999707)
- Testing
- Photon radiotherapy, Tremelimumab, Durvalumab
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma (HCC), Ovarian Cancer
NK521 in the Treatment of Advanced Solid Tumors
Eligible subjects with advanced hepatocellular carcinoma and ovarian cancer will be divided into two treatment groups based on the volume of ascites.
- Conditions
- Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites
- Trial name
- NCT07657416
- Testing
- NK521 Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Colorectal Cancer (CRC), Gastric Cancer (GC)
A Prospective Real-World Observational Study of Intratumoral Oncolytic Virus Injection Combined With Immune Checkpoint Inhibitors for Metastatic Tumors (Colorectal Cancer, Gastric Cancer, and Hepatocellular Carcinoma)
The goal of this single-arm, open-label, prospective clinical trial is to evaluate the safety, feasibility, and preliminary antitumor activity of intratumoral oncolytic virus (H101, recombinant human type 5 adenovirus) combined…
- Conditions
- Colorectal Cancer (CRC), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07850882
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jie Yuan，MD
Hepatocellular Carcinoma (HCC)
Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab
Increased pyruvate-to-lactate conversion is a hallmark of HCC metabolism. In parallel, activation of pro-inflammatory immune cells triggers a metabolic switch towards anaerobic glycolysis.
- Trial name
- NCT06605664
- Testing
- Hyperpolarized 13C pyruvate MRI
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma (HCC)
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)
- Trial name
- GPC3 (NCT06726161)
- Testing
- RYZ811, RYZ801
- Where
- 13 sites in United States
- Volunteers
- 590 people
- Sponsor
- RayzeBio, Inc.
HCC - Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study
Hepatocellular carcinoma (HCC) is one of the commonest cancers worldwide and ranks the third on the incidence of cancer-related death. There are more than 500000 new cases diagnosed annually worldwide.
- Trial name
- NCT07305428
- Testing
- Stereotactic Body Radiation Therapy followed by Immunotherapy
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
Advanced Hepatocellular Carcinoma (HCC)
HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of Adabrelimab (arterial or intravenous administration) combined with hepatic artery FOLFOX infusion chemotherapy and Bevacizumab as the first-line treatment of…
- Trial name
- HAIBrave-001 (NCT06737913)
- Testing
- HAI Adebrelimab, intravenous infusion (IV) of Adebrelimab (ADE), intravenous infusion (IV) of Bevacizumab (Bev.)
- Where
- 3 sites in China
- Volunteers
- 76 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma (HCC), Treatment Response
Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
This study aims to explore whether adding an additional MRI sequence to routine liver scans can better characterize the immune microenvironment of liver cancer.
- Trial name
- NCT07838415
- Testing
- time-dependent diffusion MRI and Cest sequence
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Tongji Hospital
HCC - Hepatocellular Carcinoma
Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer Recurrence
This study is a feasibility study about a test on adjuvant therapy for patients in hepatocellular carcinoma (HCC) with a higher risk of tumour recurrence after liver resection or ablation.
- Trial name
- NCT07839767
- Testing
- Liver-in-cube testing
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- The University of Hong Kong